Third quarter revenue of $13.1 million, representing 98% growth YoY
Raising full year 2025 revenue guidance to $49 million - $50 million
CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025.
"We delivered another strong quarter with 98% revenue growth year-over-year, expanded gross margins to 76%, increased surgeon users by more than 70% year-over-year, and reduced lead times to within 8 business days. These achievements demonstrate the incredible momentum and speed at which we are scaling while maintaining operational excellence,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “With NTAP reimbursement for cervical procedures secured and more than 50 patients treated in our clinical evaluation, we are tracking toward launching our cervical spine platform early next year to bring our transformative digital surgery approach to an even broader patient population.”
Recent Business Highlights
Reduced lead time for our aprevo® interbody implants to hospitals to within eight business days of surgical plan approval beginning October (from 10 business days exiting Q2 2025 and 20 business days in Q3 2024)
CMS New Technology Add-On Payment (NTAP) went into effect on October 1, 2025, for aprevo® cervical procedures; commercial launch is expected in early 2026. To date, over 50 cervical aprevo procedures have been successfully completed by more than a dozen spine surgeons as part of our clinical evaluation program
Data presented at the Scoliosis Research Society Annual Meeting in September demonstrated a 75% reduction in revision surgery at a two-year time point for aprevo® versus a patient matched cohort
Executed an amendment in October to our existing debt facility, increasing maximum availability to $50 million and extending the maturity date and interest-only payment period
Announced the appointment of Jennifer Kamocsay as Chief Legal Officer and Secretary. Ms. Kamocsay brings more than a decade of corporate legal experience as counsel across the life science and technology sectors
Third Quarter 2025 Financial Results
Revenue was $13.1 million for the third quarter of 2025; a 98% increase compared to $6.6 million for the third quarter of 2024
Gross profit for the third quarter of 2025 was $9.9 million compared to $4.8 million for the third quarter of 2024. Gross margin was 75.9% for the third quarter of 2025, compared with 72.8% for the third quarter of 2024
Operating expenses were $19.0 million for the third quarter of 2025, compared with $12.6 million for the third quarter of 2024, which consisted of:
Research and development expenses of $4.4 million for the third quarter of 2025, compared with $4.0 million for the third quarter of 2024
Sales and marketing expenses of $9.6 million for the third quarter of 2025, compared with $6.6 million for the third quarter of 2024
General and administrative expenses of $4.9 million for the third quarter of 2025, compared with $1.9 million for the third quarter of 2024
Net loss was ($8.5) million for the third quarter of 2025, compared to a ($7.8) million net loss for the third quarter of 2024
Adjusted EBITDA loss was ($8.2) million for the third quarter of 2025, compared to ($7.7) million for the third quarter of 2024
Cash and equivalents were $115.5 million as of September 30, 2025
2025 Full Year Financial Outlook
Revenue for the full year 2025 is expected to be in the range of $49.0 to $50.0 million, representing growth of 80% to 84% over 2024. This compares to prior guidance of $45.5 to $47.5 million.
Webcast & Conference Call Details
Carlsmed will host a conference call and concurrent webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the Company’s third quarter 2025 performance. To access the webcast, please use the following link, which will provide you with dial-in details: https://edge.media-server.com/mmc/p/y7ki9icwCarlsmed Third Quarter 2025 Earnings Conference Call.
Non-GAAP Financial Measures
This press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Carlsmed’s financial measures presented in this press release that are calculated and presented in accordance with GAAP.
The Company calculates Adjusted EBITDA as net income (loss), as adjusted to exclude (i) net interest expense and income, (ii) income tax expense (benefit), (iii) depreciation and amortization expense, (iv) stock-based compensation expense and (v) change in fair value of warrant liabilities.
This non-GAAP measure is presented because management believes it allows investors to view the Company’s performance in a manner similar to the method used by management to evaluate financial performance for both strategic and annual operating planning. Management believes that to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of Adjusted EBITDA, in addition to considering the Company’s GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of the Company’s ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare the Company’s period-over-period results.
The non-GAAP financial measures used by Carlsmed may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Carlsmed’s financial results prepared and reported in accordance with GAAP. This non-GAAP measure has limitations as an analytical tool and should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of Adjusted EBITDA reported in this press release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA” later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers.
About Carlsmed
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
Forward Looking Statement
Any statements in this press release about future expectations, plans and prospects, including statements about the Carlsmed’s ability to scale the impact of its aprevo® technology platform and advance its personalized spine surgery platform to transform patient outcomes and drive long-term growth, Carlsmed’s current expectation of commercially launching aprevo® cervical in the United States in 2026, the number ranges presented in our 2025 Full Year Financial Outlook, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in the Carlsmed’s Registration Statement on Form S-1 on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.
Investor Relations
Caroline Corner, PhD
Media
LeAnn Burton
Senior Director Brand Marketing
LBurton@Carlsmed.com
CARLSMED, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)
(unaudited)
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Revenue | $ | 13,074 | $ | 6,590 | $ | 35,346 | $ | 17,757 | ||||||||
Cost of sales | 3,147 | 1,792 | 8,914 | 4,733 | ||||||||||||
Gross profit | 9,927 | 4,798 | 26,432 | 13,024 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 4,445 | 4,035 | 11,755 | 11,289 | ||||||||||||
Sales and marketing | 9,610 | 6,622 | 24,218 | 15,092 | ||||||||||||
General and administrative | 4,907 | 1,918 | 11,715 | 6,068 | ||||||||||||
Total operating expenses | 18,962 | 12,575 | 47,688 | 32,449 | ||||||||||||
Loss from operations | (9,035) | (7,777) | (21,256) | (19,425) | ||||||||||||
Other income (expense): | ||||||||||||||||
Interest expense | (380) | (402) | (1,100) | (943) | ||||||||||||
Interest income | 954 | 394 | 1,670 | 920 | ||||||||||||
Change in fair value of warrant liabilities | (65) | (28) | (335) | (89) | ||||||||||||
Total other income (expense), net | 509 | (36) | 235 | (112) | ||||||||||||
Net loss and comprehensive loss | (8,526) | (7,813) | (21,021) | (19,537) | ||||||||||||
Deemed dividend to preferred stockholders | — | (592) | (584) | (592) | ||||||||||||
Net loss attributable to common stockholders | $ | (8,526) | $ | (8,405) | $ | (21,605) | $ | (20,129) | ||||||||
Net loss per share attributable to common stockholders, basic | $ | (0.40) | $ | (2.06) | $ | (2.15) | $ | (4.97) | ||||||||
Weighted-average number of common shares used to compute | 21,081,330 | 4,088,553 | 10,051,623 | 4,046,210 | ||||||||||||
CARLSMED, INC.
CONDENSED BALANCE SHEETS
(in thousands, except for share and par value amounts)
(unaudited)
September 30, 2025 | December 31, 2024 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 115,373 | $ | 40,125 | ||||
Restricted cash | 100 | 100 | ||||||
Accounts receivable, net of allowances of $1,601 and $1,239, as of September 30, 2025 and | 11,296 | 6,766 | ||||||
Inventory | 1,340 | 995 | ||||||
Prepaid expenses and other current assets | 3,356 | 1,365 | ||||||
Total current assets | 131,465 | 49,351 | ||||||
Property and equipment, net | 1,187 | 260 | ||||||
Operating lease right-of-use assets | 1,986 | 1,644 | ||||||
Other assets | 225 | 569 | ||||||
Total assets | $ | 134,863 | $ | 51,824 | ||||
Liabilities, Convertible Preferred Stock, and Stockholders’ Equity (Deficit) | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 2,672 | $ | 2,412 | ||||
Accrued liabilities | 3,186 | 2,687 | ||||||
Accrued compensation | 4,409 | 3,270 | ||||||
Short-term operating lease liabilities | 661 | 449 | ||||||
Total current liabilities | 10,928 | 8,818 | ||||||
Long-term portion of term loan, net | 15,440 | 15,414 | ||||||
Long-term operating lease liabilities | 1,513 | 1,317 | ||||||
Warrant liabilities | 32 | 457 | ||||||
Other long-term liabilities | 290 | 222 | ||||||
Total liabilities | 28,203 | 26,228 | ||||||
Commitments and contingencies (Note 9) | ||||||||
Series A convertible preferred stock, $0.00001 par value; zero and 4,902,814 shares authorized, issued, and outstanding, and zero and $13,767 liquidation preference as of September 30, 2025 and December 31, 2024, respectively | — | 13,578 | ||||||
Series B convertible preferred stock, $0.00001 par value; zero and 4,393,481 shares authorized, zero and 4,335,051 shares issued and outstanding, and zero and $30,000 liquidation preference as of September 30, 2025 and December 31, 2024, respectively | — | 29,801 | ||||||
Series C convertible preferred stock, $0.00001 par value; zero and 4,910,500 shares authorized, zero and 4,890,123 shares issued and outstanding, and zero and $52,500 liquidation preference as of September 30, 2025 and December 31, 2024, respectively | — | 52,847 | ||||||
Stockholders’ equity (deficit): | ||||||||
Preferred stock, $0.00001 par value; 10,000,000 and zero shares authorized, zero shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | — | — | ||||||
Common stock, $0.00001 par value; 600,000,000 and 21,835,801 shares authorized, 26,652,775 and 4,234,798 shares issued, and 26,584,077 and 4,139,219 shares outstanding as of September 30, 2025 and December 31, 2024, respectively | — | — | ||||||
Additional paid-in capital | 198,852 | 541 | ||||||
Accumulated deficit | (92,192) | (71,171) | ||||||
Total stockholders’ equity (deficit) | 106,660 | (70,630) | ||||||
Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) | $ | 134,863 | $ | 51,824 | ||||
RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA
(unaudited)
Three Months Ended September 30, | $ | % | ||||||||||||||||||
2025 | 2024 | Change | Change | |||||||||||||||||
(in thousands, except percentages) | ||||||||||||||||||||
Net loss | $ | (8,526) | $ | (7,813) | $ | (713) | 9.1% | |||||||||||||
Interest (income) expense | (574) | 8 | (582) | ** | ||||||||||||||||
Income taxes | — | — | — | — | ||||||||||||||||
Depreciation and amortization | 82 | 33 | 49 | 148.5% | ||||||||||||||||
EBITDA | (9,018) | (7,772) | (1,246) | 16.0% | ||||||||||||||||
Stock-based compensation | 704 | 66 | 638 | 966.7% | ||||||||||||||||
Change in fair value of warrant liabilities | 65 | 28 | 37 | 132.1% | ||||||||||||||||
Adjusted EBITDA | $ | (8,249) | $ | (7,678) | $ | (571) | 7.4% | |||||||||||||
Nine Months Ended September 30, | $ | % | ||||||||||||||||||
2025 | 2024 | Change | Change | |||||||||||||||||
(in thousands, except percentages) | ||||||||||||||||||||
Net loss | $ | (21,021) | $ | (19,537) | $ | (1,484) | 7.6% | |||||||||||||
Interest (income) expense | (570) | 23 | (593) | ** | ||||||||||||||||
Income taxes | — | — | — | — | ||||||||||||||||
Depreciation and amortization | 183 | 108 | 75 | 69.4% | ||||||||||||||||
EBITDA | (21,408) | (19,406) | (2,002) | 10.3% | ||||||||||||||||
Stock-based compensation | 1,137 | 153 | 984 | 643.1% | ||||||||||||||||
Change in fair value of warrant liabilities | 335 | 89 | 246 | 276.4% | ||||||||||||||||
Adjusted EBITDA | $ | (19,936) | $ | (19,164) | $ | (772) | 4.0% | |||||||||||||
** Change not meaningful